{"prompt": "['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', '11.2.', 'Perioperative Schedule of Assessments', '11.2.1.', 'Definitions of Minor and Major Surgery', 'Minor surgery is defined as any invasive operative procedure in which only skin, mucous', 'membranes, or superficial connective tissue is manipulated and does not meet the criteria for', 'major surgery (eg, dental extraction of <3 non-molar teeth). Minor surgical procedures may be', 'performed at a local health care provider institution.', 'Major surgery is defined as any invasive operative procedure that requires any of the following:', 'Opening into a major body cavity (eg, abdomen, thorax, skull)', 'Operation on a joint', 'Removal of an organ', 'Dental extraction of any molar teeth or >3 non-molar teeth', 'Operative alteration of normal anatomy', 'Crossing of a mesenchymal barrier (eg, pleura, peritoneum, dura)', 'It is recommended that any elective non-dental major surgery be performed at a clinical study', 'center, when possible.', '11.2.2.', 'Perioperative Assessments of Safety and Hemostatic Efficacy in Patients', 'Undergoing Operative Procedures', 'In patients undergoing operative procedures during the treatment period, safety and hemostatic', 'efficacy assessments will be performed according to the Perioperative Schedule of Assessments', '(described below and outlined in Table 10), where possible.', 'After a review of medical and surgery history has been completed, patients will have the', 'following assessed as specified in the Perioperative Schedule of Assessments (Table 10):', 'directed physical examination and assessment of vital sign measurements; clinical laboratory', 'assessments including hematology (complete blood count, white blood count, red blood cell', 'count, hemoglobin, hematocrit, platelets); coagulation (APTT, PT/INR, fibrinogen, D-dimer);', 'hepatic assessments; and hemostatic efficacy assessments (rating scale based on ISTH Scientific', 'and Standardization Committee [SSC] definitions). [12]', 'Property of the Sanofi Group - strictly confidential', '78']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', 'Table 10: Perioperative Schedule of Assessments in Patients Undergoing Operative', 'Procedures', 'Perioperative Evaluation Period', 'Preoperative', 'Dental/Surgical', 'Postoperative', 'Postoperative', 'Postoperative', 'Screening', 'Procedure Visit', 'Visit 1', 'Visit 2', 'Visit 3', 'SDay -3 to', 'SDay 0', 'SDay 1b', 'SDay 2 to 14c', 'SDay 28d', 'SDay -1', 'Directed', 'Physical', 'X', 'X', 'Examinationd', 'Vital Sign', 'X', 'X', 'Measurements', 'Clinical', 'Laboratory', 'X', 'Xh', 'X', 'X', 'X', 'Assessments\u00b9', 'TG', 'X', 'x g.h', 'Xk', 'Xk', 'Xk', 'AT Activity', 'X', 'X\u00b9', 'Level', 'FVIII/IX Levels8', 'X', 'X8.h', 'Xk', 'Xk', 'Xk', 'Perioperative', 'X\u00b9', 'X', 'X', 'Questionnaire', 'Completion of', 'Hemostatic', 'X\u00b9', 'X\u00b9', 'Treatment', 'Coverage', 'Note: Any operative procedure dates (SDay -3 to SDay 28) may overlap with the study Schedule of Assessments (Table 1)', 'Abbreviations: APTT=activated partial thromboplastin time; AT=antithrombin; BPA=bypassing agent; SDay=surgery day;', 'TG=thrombin generation', 'a During Perioperative Evaluation Period, AEs and concomitant medications will be collected continuously per study Schedule of', 'Assessments (Table 1).', 'b', 'Assessments to be completed within 24 hours (12 hours) from the time of end of the procedure.', 'C', 'Visit may occur anytime between SDay 2 to SDay 14, postoperatively, on a day to be determined by the Investigator. If', 'multiple visits are planned between Days 2-14 after the procedure, the perioperative questionnaire for Postoperative Visit 2', 'should be completed on the day of the last visit.', 'd Directed physical examination (see Section 7.5.3)', 'e Vital signs will be the same as conducted in the clinical study protocol Schedule of Assessments (Table 1).', 'f', 'Clinical laboratory assessments will include coagulation, hematology and biochemistry (Table 5).', 'g If factor or BPA administration and the surgical procedure occur at the study center visit, one sample should', 'be', 'collected', 'pre-', 'factor/BPA administration and two samples should be collected post-factor/BPA administration on the day the procedure. The', 'pre- factor/BPA sample may be collected any time before factor or BPA administration. The post- factor/BPA samples should', 'optimally be collected at 10 min (=5 min) and 60 min (10 min) after factor or BPA administration. The actual times of', 'collections should be recorded.', 'h', 'If the operative procedure is not performed at a study center, the assessment is recommended.', 'i', 'Not necessary if captured at preoperative screening.', 'j Hemostatic efficacy is to be assessed intraoperatively with the perioperative questionnaire on the day of the procedure (SDay 0);', 'assessment may be completed up to 8 hours postoperatively. The perioperative questionnaire will also be completed at', 'Postoperative Visit 1 and Visit 2. It is recommended that the Investigator complete this assessment in consultation with the', 'surgeon or dentist who performed the operative procedure.', 'k', 'If factor or BPA administration occurs at the study center visit, then assessments should be collected at the following time', 'points: pre-factor/BPA administration; 10 min (=5 min) post-factor/BPA administration; and 60 minutes (10 min) post-', 'factor/BPA administration. The actual times of collection should be recorded.', '1', 'The date/time of when perioperative hemostatic treatment and thromboprophylaxis (if applicable) coverage was completed will', 'be captured. If completed at Postoperative Visit 2, the date/time of completion should be recorded and the SDay 28 visit is not', 'required.', 'Property of the Sanofi Group - strictly confidential', '79']\n\n###\n\n", "completion": "END"}